

# VSTM2A reverses immunosuppression in colorectal cancer by antagonizing the PD-L1/PD-1 interaction

Yujuan Dong, Jiaxun Jade Liu, Yunfei Zhou, Wei Kang, Shanglin Li, Alvin H.K. Cheung, Yi Hu, Rui Liao, Nathalie Wong, Chi Chun Wong, Simon S.M. Ng, and Jun Yu

Correspondence: [simonng@surgery.cuhk.edu.hk](mailto:simonng@surgery.cuhk.edu.hk), [junyu@cuhk.edu.hk](mailto:junyu@cuhk.edu.hk)  
<https://doi.org/10.1016/j.ymthe.2024.10.002>

(Molecular Therapy 32, 4045–4057; November 2024)

In the original Figure 1 of this article, the schematic diagram of generation *Vstm2a* whole-body knockout mice was incorrect. The authors have used CRISPR/Cas9, but not Cre-LoxP system, for the deletion of exon 2-3 of *Vstm2a* gene. This error does not affect other figures or the conclusions of this paper. The authors sincerely apologize for any inconvenience the error may have caused.




Figure 1. Heterozygous knockout of *Vstm2a* promotes CRC development in an AOM/DSS mouse model (original)




Figure 1. Heterozygous knockout of *Vstm2a* promotes CRC development in an AOM/DSS mouse model (corrected)